title: Gene therapy strategies in glaucoma and application for steroid-induced hypertension.
abstract: Gene therapy of the eye has a high potential of becoming the preferred treatment of a number of eye diseases. Because of its easy accessibility, all the tissues of the eye can be reached and genetically manipulated with nowadays standard gene delivery technologies. Gene therapy offers the possibility to do both, correct a genetic defect by replacing the mutated or missing gene and that of using genes as drugs. Gene drugs would be more specific and would have a longer duration of action and less toxicity than conventional drugs. Examples of both applications are beginning to emerge. Using gene replacement, vision has been restored in several patients of Leber congenital amaurosis (Maguire et al., 2009). Some gene drugs, such as siRNA, are currently in clinical trials to silence angiogenic factors in macular degeneration (Campa and Harding, 2011). In this manuscript we first give a short overview of the basics of gene therapy in the eye and then review the ongoing preclinical studies in our laboratory for the gene-drug treatment of steroid-induced ocular hypertension.
authors: Department of Ophthalmology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
authors: Teresa
authors: T
authors: Borrás
keywords: Gene therapy; Glaucoma; Steroid-induced hypertension
references: Br J Ophthalmol. 1996 May;80(5):389-93
references: 8695555
references: Arch Ophthalmol. 1997 Mar;115(3):375-83
references: 9076211
references: Mol Vis. 2007 Aug 01;13:1363-74
references: 17768383
references: Int J Mol Med. 1998 Feb;1(2):339-46
references: 9852235
references: Invest Ophthalmol Vis Sci. 2009 Feb;50(2):669-73
references: 18824726
references: Annu Rev Biomed Eng. 2011 Aug 15;13:507-30
references: 21639780
references: Mol Vis. 2002 Mar 06;8:32-44
references: 11889464
references: J Gene Med. 2001 Sep-Oct;3(5):437-49
references: 11601757
references: Curr Gene Ther. 2011 Apr;11(2):116-31
references: 21291357
references: Expert Opin Biol Ther. 2011 Mar;11(3):429-39
references: 21299439
references: Fed Proc. 1965 Nov-Dec;24(6):1274-8
references: 5853148
references: Mol Ther. 2010 Mar;18(3):491-501
references: 19953083
references: Lancet. 2009 Nov 7;374(9701):1597-605
references: 19854499
references: Invest Ophthalmol. 1973 Apr;12(4):280-94
references: 4144361
references: Invest Ophthalmol Vis Sci. 2010 Jun;51(6):3042-8
references: 20089869
references: Physiol Genomics. 2009 Jul 9;38(2):205-25
references: 19401404
references: Invest Ophthalmol Vis Sci. 2010 Jun;51(6):3029-41
references: 20089870
references: Exp Eye Res. 1986 May;42(5):443-55
references: 3720863
references: Invest Ophthalmol Vis Sci. 2001 Nov;42(12):2856-60
references: 11687529
references: Invest Ophthalmol Vis Sci. 2010 Jan;51(1):236-48
references: 19684004
references: Exp Eye Res. 2009 Apr;88(4):676-82
references: 19087875
references: Physiol Rev. 2001 Jul;81(3):1269-304
references: 11427696
references: Mol Vis. 2006 Feb 27;12:125-41
references: 16541013
references: Hum Gene Ther. 2011 May;22(5):559-65
references: 21175295
references: Exp Eye Res. 2006 Jun;82(6):935-44
references: 16442523
references: Curr Drug Targets. 2011 Feb;12(2):173-81
references: 20887245
references: Hum Gene Ther. 2011 Oct;22(10):1191-200
references: 21542676
references: Blood. 2005 Feb 15;105(4):1424-30
references: 15507527
references: Invest Ophthalmol Vis Sci. 1998 Dec;39(13):2649-58
references: 9856774